Eslicarbazepine in patients with brain tumor-related epilepsy: a single-center experience

References

• van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421–430.
   PubMed Web of Science ®Google Scholar
• Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 2013;54:97–104.
   PubMed Web of Science ®Google Scholar
• Maschio M, Aguglia U, Avanzini G, et al. Management of epilepsy in brain tumors. Neurol Sci. 2019;40(10):2217–2234.
   PubMed Web of Science ®Google Scholar
• Breemen MSM, Rijsman RM, Taphoorn MJB, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–1526.
   PubMed Web of Science ®Google Scholar
• Rudà R, Trevisan E, Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol. 2010;22(6):611–620.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2019. Zebinix® (eslicarbazepine acetate). Summary of product characteristics.
   Google Scholar
• Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007;48(3):497–504.
   PubMed Web of Science ®Google Scholar
• Elger C, Halász P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50(3):454–463.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gabbai AA, Hufnagel A, et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2–3):278–285.
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120(5):281–287.
   PubMed Web of Science ®Google Scholar
• Sperling MR, Abou-Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56(2):244–253.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Serratosa JM, Guillamón E, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res. 2014;108(7):1243–1252.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Holtkamp M, Delanty N, et al. Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures. J Neurol. 2017;264(11):2232–2248.
   PubMed Web of Science ®Google Scholar
• Gómez-Ibáñez A, Serratosa JM, Guillamón E, et al. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: case series. Seizure. 2017;48:53–56.
   PubMed Web of Science ®Google Scholar
• Maschio M, Dinapoli L, Mingoia M, et al. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol. 2011;258(11):2100–2104.
   PubMed Web of Science ®Google Scholar
• Rudà R, Pellerino A, Franchino F, et al. Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. J Neurooncol. 2018;136(1):105–114.
   PubMed Web of Science ®Google Scholar
• Maschio M, Zarabla A, Maialetti A, et al. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group. Epilepsy Behav. 2019;73:83–89.
   Web of Science ®Google Scholar
• Maschio M, Pauletto G, Zarabla A, et al. Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. Int J Neurosci. 2019;129(6):593–597.
   PubMed Web of Science ®Google Scholar
• Marcuse LV, Lancman G, Demopoulos A, et al. Nonconvulsive status epilepticus in patients with brain tumors. Seizure. 2014;23(7):542–547.
   PubMed Web of Science ®Google Scholar
• Hebeisen S, Pires N, Loureiro AI, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015;89:122–135.
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics. 2007;4(1):88–96.
   PubMed Web of Science ®Google Scholar
• Nunes T, Rocha JF, Falcão A, et al. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013;54(1):108–116.
   PubMed Web of Science ®Google Scholar
• Sabaté E, World Health Organization. 2003. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization.
   Google Scholar
• Armstrong TS, Vera-Bolanos E, Acquaye AA, et al. The symptom burden of primary brain tumors: evidence for a core set of tumor-and treatment-related symptoms. Neuro Oncol. 2016;18(2):252–260.
   PubMed Web of Science ®Google Scholar
• Bialer M, Soares-Da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935–946.
   PubMed Web of Science ®Google Scholar
• Maschio M. Brain tumor-related epilepsy. CN. 2012;10(2):124–133.
   Web of Science ®Google Scholar
• Gierbolini J, Giarratano M, Benbadis SR. Carbamazepine-related antiepileptic drugs for the treatment of epilepsy: a comparative review. Expert Opin Pharmacother. 2016;17(7):885–888.
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Elger C, Ben-Menachem E, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia. 2013;54(1):98–107.
   PubMed Web of Science ®Google Scholar